-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
WCLC News
-
IASLC Journals See Continued Success Throughout Past Year
Editors-in-Chief Drs. Alex A. Adjei and Emily Stone will talk with members during a Meet-the-Editor session on Monday afternoon.
-
Hands-on Workshop Outlines Challenges and Potential Solutions for Translating Early Detection Biomarkers From Discovery to Lung Cancer Clinical Practice
An expert panel from the US National Cancer Institute’s Early Detection Research Network provided insights into the current state of the art as well as barriers to use.
-
Updated Biomarker Survey Results Show Paradigm Shift As More Respondents Now Consider Testing a “Must Have”
However, lead author Dr. Matthew Smeltzer said the new data also show clinicians value biomarker testing more in late-stage disease compared to early-stage disease.
-
9th Edition Lung Cancer Staging Recommendations to be Explained
During the session, experts will not only review the updates, they will also discuss how they approached the process and the guidelines’ limitations.
-
Special Plenary to Focus on IASLC’s Role in Shaping Thoracic Cancer Research, Treatment
Former IASLC CEO Dr. Paul A. Bunn, Jr., says lung cancer is a global challenge and the unique multinational and multi-specialty nature of the IASLC has helped to build a global response.
-
Learn and Network During Poster Viewing Events
The WCLC 2024 program includes several opportunities to browse posters and see the latest in thoracic oncology research.
-
First Presidential Symposium to Explore Practice-Changing Research in Lung Cancer Screening, Immune Oncology
The session will also include late-breaking data from HARMONi-2, NeoCOAST-2, and TROPION-Lung01 as well as an address from IASLC President Dr. Paul Van Schil.
-
Action Needed to Improve Gender Equity in Thoracic Oncology
While women remain a minority in thoracic oncology, Drs. Narjust Florez and Linda Martin say change is happening. The duo will co-chair a special session designed to address issues faced by women in the field.
-
IASLC President-Elect Reflects on Importance of Prevention, Screening, Biomarker Testing and More
Dr. Caicun Zhou discusses his plans for WCLC 2024 as well as his goals for his time as IASLC President.
-
Empowering Change and Amplifying Impact Through Research Advocacy Activities
In a Q&A with ILCN, patient advocate Isaac Joseph discusses the importance of patient advocacy in resource-limited settings.